超声波敏感的脂质体外用于瘤特异性药物释放,用于治疗胰腺癌
Dongyeon Kim1, Hyungwon Moon2, Sunyoung Han2
1Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
超声敏脂质体 (IMP305) 通过在腔化时释放药物来增强胰腺癌的药物输送. 这种方法可以提高药物透率和抗瘤效果,同时降低毒性.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种致命的癌症,由于密集的肌层,在药物输送方面存在挑战.
- IMP305是一种超声敏脂质体,旨在在瘤中局部释放药物.
- 超声波介导的化是IMP305.5中药物释放的主要机制.
研究的目的:
- 评估IMP305能够将瘤特异性药物输送与通过空洞化松动的树皮松动相结合的能力.
- 在PDAC模型中评估IMP305增强的内释放药物和抗瘤功效.
主要方法:
- 开发IMP305,一种超声波敏感的脂质体,可以封装exatecan.
- 在PANC-1异种移植小鼠模型中进行测试,以评估药物释放和治疗效果.
- 使用IMP305和聚焦超声波评估协同效益的组合疗法.
主要成果:
- 在IMP305中封装增加了exatecan.can的最大耐受剂量.
- 腔化引发了IMP305 (84.68%) 和药物释放 (84.4%) 的显著结构破坏.
- 与免费埃克萨特干相比,IMP305表现出优异的抗瘤活性和更高的最大耐受剂量,组合治疗显示出最显著的瘤体积减少 (49.17%) 和存活率 (80%).
结论:
- 超声波激活的IMP305有效地增强了内甲酸的积累和释放.
- 在PDAC模型中,IMP305提供了优越的瘤抑制,并降低了全身毒性.
- 这项技术为改善胰腺癌治疗结果提供了一个有希望的策略.
更多相关视频
06:57Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
07:31Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
相关概念视频
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Drugs Affecting Neurotransmitter Release or Uptake
Treatment Resistant Cancers
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
